

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A therapeutic agent for cancer, wherein a tyrosine kinase inhibitor and an IL-12 inducer are used in combination.
2. (original) The therapeutic agent for cancer according to claim 1, wherein the tyrosine kinase inhibitor has a selective targeting action on at least one receptor selected from the group consisting of the following 1) to 7):

1) HER2/neu; 2) HER3; 3) HER4; 4) c-kit; 5) PDGFR; 6) bcr-abl; and 7) EGFR.
3. (original) The therapeutic agent for cancer according to claim 1, wherein the tyrosine kinase inhibitor has an action with EGFR or c-kit selectively targeted.
4. (currently amended) The therapeutic agent for cancer according to ~~any one of~~ claim 1 to 3, wherein the IL-12 inducer is a substance having a β 1,3-1,6 glucan structure.
5. (original) The therapeutic agent for cancer according to claim 4, wherein the IL-12 inducer is a yeast-derived ingredient or an ingredient derived from mushroom mycelium that has a β 1,3-1,6 glucan structure.

6. (currently amended) The therapeutic agent for cancer according to ~~any one of claim 1 to 5~~, which is used in no combination with a chemotherapeutic agent for cancer and a radiation therapy.

7. (currently amended) The therapeutic agent for cancer according to ~~any one of claim 1 to 6~~, which is used in combination with a substance that selectively acts on NKR-P1 of NKT cell to cause activation of NKT cell.

8. (currently amended) The therapeutic agent for cancer according to ~~any one of claim 1 to 7~~, which is used in combination with a substance having neovascularization inhibiting capabilities.

9. (currently amended) The therapeutic agent for cancer according to ~~any one of claim 1 to 8~~, wherein a treatment that combines use of a tyrosine kinase inhibitor and an IL-12 inducer is carried out employing either one of the following 1) and 2) as a marker:

1) an NKTP value before administration showing a measurement value of 5% or more;

2) a Th2 value before administration showing a measurement value of 3% or more.

10. (currently amended) The therapeutic agent for cancer according to ~~any one of claim 1 to 9~~, wherein a Th1/Th2 ratio that shows an increased measurement value after several months of administration of IRESSA in comparison to a value before administration of IRESSA is taken as a marker for continuation of the combined treatment.

11. (original) The therapeutic agent for cancer according to claim 10, wherein an NKTP value before administration shows a measurement value below 5%.

12. (original) The therapeutic agent for cancer according to claim 9, wherein a marker for continuation of the combined treatment is that measurement values of IL-12 and INF γ after several months of administration of IRESSA have not decreased in comparison with measurement values thereof before administration of IRESSA.

13. (currently amended) The therapeutic agent for cancer according to ~~any one of claim 1 to 12~~, wherein the therapeutic agent for cancer is a therapeutic agent for pulmonary adenocarcinoma.

14. (currently amended) A therapeutic method for cancer comprising administering ~~that uses~~ the therapeutic agent for cancer according to ~~any one of claim 1 to 13~~.

15. (new) The therapeutic agent for cancer according to claim 2, wherein the IL-12 inducer is a substance having a β 1,3-1,6 glucan structure.

16. (new) The therapeutic agent for cancer according to claim 3, wherein the IL-12 inducer is a substance having a β 1,3-1,6 glucan structure.

17. (new) The therapeutic agent for cancer according to claim 2, which is used in combination with a substance that selectively acts on NKR-P1 of NKT cell to cause activation of

NKT cell.

18. (new) The therapeutic agent for cancer according to claim 3, which is used in combination with a substance that selectively acts on NKR-P1 of NKT cell to cause activation of NKT cell.

19. (new) The therapeutic agent for cancer according to claim 2, wherein a Th1/Th2 ratio that shows an increased measurement value after several months of administration of IRESSA in comparison to a value before administration of IRESSA is taken as a marker for continuation of the combined treatment.

20. (new) The therapeutic agent for cancer according to claim 3, wherein a Th1/Th2 ratio that shows an increased measurement value after several months of administration of IRESSA in comparison to a value before administration of IRESSA is taken as a marker for continuation of the combined treatment.